While the COVID-19 impact varies by study and program, generally, the company expects there will be little timing impact on fully-enrolled trials and a timing shift of at least three months on trials. The company is exploring the potential role of Ultomiris and Soliris for the treatment of severe COVID-19 and has recently initiated a Phase 3 randomized controlled trial of Ultomiris in a subset of adults with coronavirus.
Looking ahead into the full-year 2020, the company lowered its total revenues outlook to the range of $5.23-5.33 billion from the previous range of $5.5-5.56 billion, and its adjusted EPS guidance to the range of $10.45-10.75 from the prior range of $10.65-10.85. The GAAP EPS forecast is tightened to the range of $8.14-8.47 from the prior range of $7.91-8.71.